Dosage Forms

Articles

CHMP has recommended that Ervebo (rVSVΔG-ZEBOV-GP), a vaccine for active immunization against Ebola, be granted conditional marketing authorization in the EU.

First Ebola Vaccine Gains Conditional Marketing Authorization Recommendation

Agnes Shanley is senior editor of Pharmaceutical Technology.

Antimicrobial resistance is now the third leading cause of death in the US. As developers continue to leave an unprofitable market, legislation and new reimbursement models propose to stimulate development of new antibiotics.

Restoring the World's Antibiotic Pipeline

The agency announced that FDA scientists have developed candidate vaccine viruses that may be used to produce influenza vaccines.

FDA Develops Candidate Vaccine Viruses

The project will focus on the development of an influenza vaccine that protects against multiple strains of the influenza virus in a single dose.

NIH Awards The University of Georgia Up to $130 Million for Flu Vaccine

Procarta Biosystems has received an award from CARB-X, potentially worth $9.2 million, for the development of antibiotic precision medicines.


UK Biotech Receives CARB-X Award Worth $9.2 Million

In parallel to the priority review designation for its biologics license application, Merck plans to scale up its doses of the investigational Ebola vaccine to meet global outbreak response needs.

Merck & Co.’s Application for Ebola Vaccine Accepted by FDA and Granted Priority Review

The company has received breakthrough therapy designation for its prophylactic respiratory syncytial virus vaccine candidate for treating adults aged 60 years or older.

Janssen Gets FDA Breakthrough Therapy Designation for RSV Vaccine

Valo Therapeutics has acquired a technology from Helsinki University that is expected to broaden its approach and expand the capability of its cancer vaccines platform, PeptiCRAd.


Valo Therapeutics Acquires Technology from Helsinki University

The new facility, located in Ness Ziona, Israel, will support clinical phage manufacturing and can be expanded in the future to support commercial-scale manufacturing.

BiomX Completes In-House Phage Manufacturing Facility

Wendy Saffell-Clemmer, BPS, is research director, R&D and innovation, at Baxter Healthcare.

Elizabeth Joseph is research scientist II, BioPharma Solutions at Baxter Healthcare Corporation.

The authors provide an introduction to aluminum adsorbed vaccines, review studies of antigen stability, and propose test methods for the analysis of aluminum vaccine release and stability analysis.

Vaccines